Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?

Nadine KronfliJim YoungShouao WangJoseph CoxSharon WalmsleyMark HullCurtis CooperValerie Martel-LaferriereAlexander WongNeora PickMarina B Kleinnull null

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

TE should be the preferred noninvasive tool for monitoring fibrosis regression following cure. Future studies should assess the risk of liver-related outcomes such as hepatocellular carcinoma according to trajectories of fibrosis regression measured using TE to determine if and when it will become safe to discontinue screening.

Keyphrases

human immunodeficiency virus
hepatitis c virus
liver fibrosis
antiretroviral therapy
hiv infected
hiv positive
hiv aids
depressive symptoms
hiv testing
skeletal muscle
case control
drug induced